David L. Bourdet
0000-0001-6220-1922
Publication & Citation Trends
Publications
0 total
Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial OA
Cited by 5
Semantic Scholar
The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation OA
Cited by 2
Semantic Scholar
P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study OA
Cited by 2
Semantic Scholar
The Safety, Pharmacokinetics, and Pharmacodynamics of TD-8236, an Inhaled pan-JAK Inhibitor: Results from Part C of a First-in-Human Study in Participants with Moderate to Severe Asthma
Cited by 1
Semantic Scholar
Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species OA
Cited by 4
Semantic Scholar
Tu1447: IZENCITINIB INDUCTION TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Cited by 0
Semantic Scholar
A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1 OA
Cited by 3
Semantic Scholar
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics
Cited by 3
Semantic Scholar
Research Topics
Drug Transport and Resistance Mechanisms
(9)
Inhalation and Respiratory Drug Delivery
(8)
Pharmacogenetics and Drug Metabolism
(7)
Asthma and respiratory diseases
(6)
COVID-19 Clinical Research Studies
(4)
Affiliations
University of North Carolina at Chapel Hill
Bristol-Myers Squibb (United States)
Theravance Biopharma (United States)
Roche (Bosnia-Herzegovina)
La Roche College